Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Myeloid 1Lymphoid 1

Conditions

Recurrence 2Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cytarabine 465Cyclophosphamide 459fludarabine phosphate 277Rituximab 249Methotrexate 245Etoposide 203fludarabine 200Filgrastim 199Peripheral Blood Stem Cell Transplantation 180Busulfan 169Vincristine 163Dexamethasone 153Daunorubicin 151Azacitidine 145Mycophenolic Acid 142Whole-Body Irradiation 133Tacrolimus 127Imatinib Mesylate 127Cyclosporine 123Granulocyte Colony-Stimulating Factor 118Radiotherapy 113Melphalan 110Idarubicin 103Doxorubicin 101Mitoxantrone 97Decitabine 97Antilymphocyte Serum 97Lenalidomide 96Mercaptopurine 93Prednisone 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × CYC065 × Other hematologic neoplasm × Clear all
NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
14 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
5 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡